Recruiting Mirdametinib in Patients With Advanced NF1-mutant Melanoma NCT07237100 Conditions Advanced Unresectable Melanoma, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +21 more Locations California Pacific Medical Center - Sutter Health — San Francisco, California, United States View Trial Details
